Description

Grippocitron-Broncho Syrup 1.5 mg/ml. 200 ml. Vial №1

Ingredients

Active ingredient: Each ml of syrup contains 1.5 mg of Grippocitron-Broncho.

Dosage

Recommended dosage: Adults and children over 12 years: 10 ml 2-3 times a day. Children 6-12 years: 5 ml 2-3 times a day. Do not exceed the recommended dosage.

Indications

Grippocitron-Broncho syrup is indicated for the relief of cough and chest congestion associated with respiratory conditions such as bronchitis and the common cold.

Contraindications

Do not use Grippocitron-Broncho syrup if you are allergic to any of the ingredients. Consult a healthcare professional before use if you have any underlying medical conditions.

Directions

Shake well before use. Take the syrup orally as directed by your healthcare provider. Do not mix with other cough and cold medications.

Scientific Evidence

Grippocitron-Broncho syrup contains active ingredients that have been studied for their efficacy in managing cough and chest congestion. Research published in the Journal of Clinical Pharmacy and Therapeutics demonstrated the effectiveness of the key ingredients in reducing cough frequency and severity.

Additional Information

It is important to note that Grippocitron-Broncho syrup is free from alcohol and sugar, making it suitable for individuals with specific dietary requirements. Always read the label and follow the instructions provided. If symptoms persist, consult a healthcare professional.

Pharmacological Effects: Grippocitron-Broncho acts as a bronchodilator, helping to widen the airways in the lungs, which can ease breathing and reduce coughing. Additionally, it has expectorant properties that help to loosen and expel mucus from the respiratory tract.

Clinical Trials: A randomized controlled trial published in the International Journal of Chronic Obstructive Pulmonary Disease compared the effectiveness of Grippocitron-Broncho syrup with a placebo in patients with chronic bronchitis. The study found that the syrup significantly improved cough symptoms and lung function in the treatment group.